Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer
Conditions: Pancreatic Adenocarcinoma Metastatic Interventions: Drug: Penpulimab; Drug: Anlotinib; Drug: Nab paclitaxel; Drug: Gemcitabine Sponsors: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Conditions: Solid Tumor, Adult; Colorectal Cancer; NSCLC; Non Small Cell Lung Cancer; NSCLC, Recurrent; Non-Small Cell Squamous Lung Cancer; Pancreas Cancer; Pancreatic Neoplasm; Colorectal Adenocarcinoma; CRC; Colon Cancer; Rectal Cancer; Cancer; Ovarian Cancer; Ovarian Neoplasms; Mesothelioma; Mesothelioma, Malignant; Ovary Cancer; Lung Cancer; MESOM Interventions: Biological: A2B694; Diagnostic Test: xT CDx with HLA-LOH Assay Sponsors: A2 Biotherapeutics Inc.; Tempus Labs Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
Factors Affecting the Results of Treatment of Patients With Colorectal Cancer
Conditions: Colorectal Cancer; Colon Cancer; Rectal Cancer; Colorectal Adenocarcinoma; Colorectal Neoplasms Malignant; Rectal Adenocarcinoma Interventions: Procedure: Right hemicolectomy; Procedure: Left hemicolectomy; Procedure: Sigmoid colon resection; Procedure: Anterior resection of the rectum; Procedure: Low anterior resection of the rectum; Procedure: Abdominoperineal resection; Procedure: Total Colecto my Sponsors: Immanuel Kant Baltic Federal University; Center of Endourology " Endocenter " Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 22, 2023 Category: Research Source Type: clinical trials
Factors Affecting the Results of Treatment of Patients With Colorectal Cancer
Conditions: Colorectal Cancer; Colon Cancer; Rectal Cancer; Colorectal Adenocarcinoma; Colorectal Neoplasms Malignant; Rectal Adenocarcinoma Interventions: Procedure: Right hemicolectomy; Procedure: Left hemicolectomy; Procedure: Sigmoid colon resection; Procedure: Anterior resection of the rectum; Procedure: Low anterior resection of the rectum; Procedure: Abdominoperineal resection; Procedure: Total Colectomy Sponsors: Immanuel Kant Baltic Federal University; Center of Endourology " Endocenter " Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 22, 2023 Category: Research Source Type: clinical trials
Early Access Program for Zolbetuximab
Conditions: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma Cancer; Metastatic Gastric Adenocarcinoma Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma Intervention: Drug: zolbetuximab Sponsor: Astellas Pharma Global Development, Inc. Available (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
Condition: Pancreatic Ductal Adenocarcinoma Interventions: Radiation: Stereotactic body radiotherapy (SBRT); Drug: Zimberelimab; Drug: Quemliclustat; Drug: Etrumadenant; Drug: Modified FOLFIRINOX Sponsors: Gulam Manji; Arcus Biosciences, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Adenocarcinoma
Conditions: Adenocarcinoma Esophagus; Locally Advanced Adenocarcinoma; Siewert Type I Adenocarcinoma of Esophagogastric Junction; Siewert Type II Adenocarcinoma of Esophagogastric Junction Interventions: Drug: Vactosertib; Drug: Standard of Care Chemotherapy; Radiation: Concurrent Radiation Sponsor: Jennifer Eva Selfridge Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
PSMA PET Response Guided SabR in High Risk Pca
Condition: Prostate Adenocarcinoma Intervention: Drug: 68-Ga PSMA11 Sponsors: University of Texas Southwestern Medical Center; Once Upon a Time Foundation; Telix International Pty Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.
Conditions: Prostatic Neoplasm; Adenocarcinoma; Neoplasm Recurrence; Neoplasm Metastasis Intervention: Other: Standard care Sponsors: Centre Hospitalier Universitaire de Pointe-a-Pitre; Institut National de la Santé Et de la Recherche Médicale, France Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
